1887

Chapter 44 : Fluoroquinolones and Tuberculosis: a Review

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Fluoroquinolones and Tuberculosis: a Review, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap44-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap44-2.gif

Abstract:

Some fluoroquinolones have been demonstrated to be effective companions in standard regimens of tuberculosis (TB) therapy, but the emergence of isolates resistant to fluoroquinolones, all of them having a cross-resistance, has led to discontinuation of their use in monotherapy. In a study, Tosufloxacin, a 1,8-naphthyridone compound, was shown to be inactive against 98 isolates of in a nonspecified agar medium. In this study, it was shown that in vitro sparfloxacin was the most active compound against all isolates. The in vitro activities of balofloxacin, cadrofloxacin (CS-940), and other fluoroquinolones against 100 isolates were assessed using an egg-based Ogawa medium and 7H10 Middlebrook agar medium. Fluoroquinolones are widely distributed in tissue, including within cells, where resides. Moxifloxacin at 20 mg/kg daily allowed a 100% survival rate, in comparison with a 50% survival rate in control mice after challenge with a large inoculum of the virulent strain CSU 98. It has been shown in murine infection induced by H37 that among the fluoroquinolones and aminoglycosides, sparfloxacin at 50 mg/kg and amikacin at 200 mg/kg are the most active compounds after isoniazid (25 mg/kg) in treating TB in mice. The most active compound is PD-161144-like gatifloxacin, which was reported to show good antimycobacterial activity.

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815929.ch44
1. Ainsa JA,, Blockpoel MC,, Otul I,, Young DB,, De Smet A,, Martin C, 1998, Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis, J Bacteriol, 180, 58365843.
2. Alangaden GJ,, Lerner SA, 1997, The clinical use of fluoroquinolones for the treatment of mycobacterial diseases, Clin Infect Dis, 25, 12131221.
3. Alangaden GJ,, Manavathu EK,, Vakulenko SB,, Zvonok NM,, Lerner SA, 1995, Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients, Antimicrob Agents Chemother, 39, 17001703.
4. Alegre J,, Fernandez de, Sevilla T,, Faka V,, Martinez-Vazquez JM, 1990, Ofloxacin in miliary tuberculosis, Eur Resp J, 3, 238239.
5. American Thoracic Society, 1994, Treatment of tuberculosis and tuberculosis infection in adults and children, Am J Resp Crit Care, 149, 13591374.
6. Andriole VT, 1989, An update on the efficacy of ciprofloxacin in animal models of infection, Am J Med, 87, Suppl 5A, 532534.
7. Artico M,, Mai A,, Sbardella G,, Massa S,, Misiu C,, Lostia S,, Demontis F,, La Colla P, 1999, Nitroquinolones with broad spectrum antimycobacterial activity in vitro, Bioorg Med Chem Lett, 8, 16511656.
8. Bagnato GF,, Di Cesare E,, Gulli S,, Cucinotta D, 1995, Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis, Monaldi Arch Chest Dis, 50, 279281.
9. Banerjee DK,, Ford J,, Makanday S, 1992, In vitro activity of lome-floxacin against pathogenic and environmental mycobacteria, J Antimicrob Chemother, 30, 236238.
10. Banerjee SK,, Bhatt K,, Rana S,, Misra P,, Chakraborti PK, 1996, Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis, Biochem Biophys Res Commun, 226, 362368.
11. Bergstermann H,, Rüchardt A, 1997, Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis, Infection, 25, 227232.
12. Berlin OGW,, Young LS,, Bruckner DA, 1987, In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis, J Antimicrob Chemother, 19, 611615.
13. Bermudez LE,, Goodman J, 1996, Mycobacterium tuberculosis invades and replicates within type II alveolar cells, Infect Immun, 64, 14001406.
14. Berning SE, 2001, The role of fluoroquinolones in tuberculosis today, Drugs, 61, 918.
15. Berning SE,, Cherry TA,, Iseman MD, 2001, Novel treatment of meningitis caused by multidrug resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin, case report, Clin Infect Dis, 32, 643646.
16. Berning SE,, Huitt GA,, Iseman MD, et al, 1992, Malabsorption of antituberculous medications by patients with AIDS, New Engl J Med, 327, 18171818.
17. Berning SE,, Madsen L,, Iseman MD,, Peloquin CA, 1995, Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infection, Am J Respir Crit Care Med, 151, 20062009.
18. Bhatti N,, Chronos N,, White JP,, Larson E, 1990, A case of resistant tuberculosis, Tubercle, 71, 141143.
19. Borges-Walmsley MI,, Walmsley AR, 2001, The structure and function of drug pumps, Trends in Microbiol, 9, 19.
20. Bothamley G, 2001, Drug treatment for tuberculosis during pregnancy—safety considerations, Drug Safety, 24, 553565.
21. Cambau E,, Sougakoff W,, Bessen M,, Truffot-Pernot C,, Grosset J,, Jarlier V, 1994a, Selection of gyr A mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin, J Infect Dis, 170, 479483.
22. Cambau E,, Sougakoff W,, Jarlier V, 1994b, Amplification and nucleotide sequence of the quinolone determining region in the gyr A gene of mycobacteria, FEMS Microbiol Lett, 116, 4954.
23. Canetti G,, The J, 1965, Burns Ambersen Lecture, present aspects of bacterial resistance in tuberculosis, Am Rev Resp Dis, 92, 687703.
24. Caparros-Lefebvre D,, Salomez JL,, Petit H, 1989, Tuberculomes intracrâniens multiples: aspect en imagerie par résonance magnétique nucléaire et apport thérapeutique de l’ofloxacine, Ann Med Inter, 140, 699701.
25. Casal M,, Gutierrez J,, Ruiz P,, Morena G, 1995, Preliminary study of the in vitro activity of irloxacin against mycobacteria, Chemotherapy, 41, 204207.
26. Chadwick M,, Nicholson G,, Gaya H, 1989, Brief report, combination chemotherapy with ciprofloxacin for infection with M. tuberculosis in a mouse model, Am J Med, 87, suppl 5A, 535536.
27. Chaulet P,, Raviglione M,, Bustero F, 1996, Epidemiology, control and treatment of multidrug resistant tuberculosis, Drugs, 52, suppl 2, 103108.
28. Chen C-H,, Shih J-F,, Lindholm-Levy PJ,, Heifets LB, 1989, Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolates before treatment of patients in Taiwan, Am Rev Respir Dis, 140, 987989.
29. Cole ST,, Brosch R,, Parkhill J,, Garnier T,, Churche C,, Harris D, et al, 1998, Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature, 393, 537544.
30. Collins CH,, Yates MD,, Uttley AMC, 1985, In vitro susceptibility of mycobacteria to ciprofloxacin, Antimicrob Chemother, 16, 575580.
31. Cooksey RC,, Crawford JT,, Jacobs WR Jr,, Shinnick TM, 1993, A rapid method for activity against a strain of M. tuberculosis expessing firefly luciferase, Antimicrob Agents Chemother, 37, 13481352.
32. Crofton J,, Choculet P,, Maher D, et al, 1997, Guidelines for the management of drug-resistant tuberculosis WHO/TB/96-210 (rev 1), World Health Organization, Geneva.
33. Crowle AJ,, Elkins N,, May MH, 1988, Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium and rifampicin against M. tuberculosis in cultured human macrophages, Am Rev Resp Dis, 137, 11411146.
34. Dailloux M,, Petitpain N,, Henry C,, Weber M, 1989, Détermination in vitro de la sensibilité des mycobactéries aux fluoroquinolones, Path Biol, 37, 346349.
35. Dautzenberg B,, Truffot-Pernot C,, Bakdach H, 1994, Ambulatory regimen with sparfloxacin and combined old antituberculosis drugs plus synergy for treatment of multidrug resistant tuberculosis, Tubercle Lung Dis, 75, Suppl 1, 14 AB, 47.
36. Davies S,, Sparham PD,, Spencer RC, 1987, Comparative in vitro activity of five fluoroquinolones against mycobacteria, J Antimicrob Chemother, 19, 605609.
37. De Angelis CM, 1981, Intracranial tuberculoma, case report and review of the literature, Neurology, 31, 11331136.
38. Dong Y,, Xu C,, Zhao X,, Domagala J,, Drlica K, 1998, Fluoroquinolone action against mycobacteria; effects of C-8 substituents on growth, survival, and resistance, Antimicrob Agents Chemother, 42, 29782984.
39. Dong Y,, Xu C,, Zhao X,, Domagala J,, Drlica K, 1999, Effect of fluoroquinolone concentration on selection of mutants of Mycobacterium bovis BCG and Staphylococcus aureus, Antimicrob Agents Chemother, 43, 17561758.
40. Drlica K,, Xu C,, Wang JY,, Burger RM,, Malik M, 1996, Fluoroquinolone action in mycobacteria, similarity with effects in Escherichia coli and the detection by cell lysate viscosity, Antimicrob Agents Chemother, 40, 15941599.
41. Esihi H,, Vincent V,, Cole ST, 1996, Homing events on the gyr A gene of some mycobacterials, Proc Natl Acad Sci USA, 93, 34103415.
42. Estebanez Zarranz MJ,, Martinez Sagarra JM,, Alberte A,, Amon Sesmero J,, Rodriguez Toves A, 1992, Treatment of urogenital tuberculosis with ofloxacin, preliminary study, Actas Urol Esp, 16, 6468, in Spanish.
43. Fenleon CH,, Cynamon MH, 1986, Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare, Antimicrob Agents Chemother, 29, 386388.
44. Fung-Tomc J,, Minassian B,, Kolek B,, Washo T,, Huczko E,, Bonner D, 2000, In vitro antibacterial spectrum of a new 8-methoxyfluoroquinolone, gatifloxacin, J Antimicrob Chemother, 45, 437446.
45. Fur A,, Massin P,, Camus A,, Waldner A,, Jeanin L, 1987, Traitement de sauvetage d’une tuberculose pulmonaire multirésistante: efficacité de la péfloxacine, Presse Med, 3, 128.
46. Gagnerie F,, Taillan B,, Euller-Ziegler G, 1988, Efficacité transitoire de la péfloxacine au cours d’une ostéoarthrite tuberculeuse, Med Mal Infect, 18, 201202.
47. Garcia-Rodriguez JA,, Garcia-Gomez AC, 1993, In vitro activities of quinolones against mycobacteria, J Antimicrob Chemother, 32, 797808.
48. Garcia-Rodriguez JA,, Garcia-Sanchez JF,, Gomez-Garcia AC,, Trujillano I,, Plata AM, 1988, In vitro activity of the new quinolones, with special reference to Mycobacterium, Nocardia and Rhodococcus, Rev Infect Dis, 10, suppl 1, S53S55.
49. Gay JD,, De, Young DR,, Roberts GD, 1984, In vitro activity of nor-floxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii, Antimicrob Agents Chemother, 26, 9496.
50. Gaya H,, Chadwick MV, 1986, In vitro activity of ciprofloxacin against mycobacteria, Eur J Clin Microbiol, 4, 345347.
51. Gevaudan MJ,, Mallet MN,, Gulian C,, Terriou P,, Lagier P,, de Micco P, 1998, Etude de la sensibilité de sept espèces de mycobactéries aux nouvelles quinolones, Path Biol, 36, 477481.
52. Gillespie SH,, Kennedy N, 1998, Fluoroquinolones, a new treatment for tuberculosis, Int J Tuberc Lung Dis, 2, 265271.
53. Girling DJ, Hong Kong Chest Service/British Medical Research Council, 1992, A controlled study of a ribafutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin, Tubercle Lung Dis, 73, 5967.
54. Gorzynski EA,, Gutman SI,, Allen W, 1989, Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones and a new macrolide, clarithromycin, Antimicrob Agents Chemother, 33, 591592.
55. Grassi C, 1997, New drugs for tuberculosis, Exp Opin Investig Drugs, 6, 12111226.
56. Grosset JH, 1992, Treatment of tuberculosis in HIV infection, Tubercle Lung Dis, 73, 378383.
57. Guillemin I,, Jarlier V,, Cambau E, 1998, Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria, Antimicrob Agents Chemother, 42, 20842088.
58. Guillemin I,, Sougakoff W,, Cambau E,, Viravau VR,, Moreau N,, Jarlier V, 1999, Purification and inhibition by quinolones of DNA gyrase from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum, Microbiology, 145, 25272532.
59. Haemers A,, Leysen DC,, Bollaert W,, Zhang M,, Pattyn SR, 1990, Influence of N-substitution on antimycobacterial activity of ciprofloxacin, Antimicrob Agents Chemother, 34, 496497.
60. Heifets LB,, Lindholm-Levy PJ, 1987, Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex, Tubercle, 68, 267276.
61. Heifets LB,, Lindholm-Levy PJ, 1990, MICs and MBCs of WIN 57273 against Mycobacterium avium and Mycobacterium tuberculosis, Antimicrob Agents Chemother, 34, 770774.
62. Hoffner SE,, Gezelius L,, Olsson-Liljequist B, 1997, In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis, J Antimicrob Chemother, 40, 885888.
63. Horn DL,, Hewlett D,, Alfalla C, et al, 1994, Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis [letter], N Engl J Med, 330, 1241.
64. Hussey G,, Kibel M,, Parker N, 1992, Ciprofloxacin treatment of multiply drug-resistant extrapulmonary tuberculosis in a child, Pediatr Infect Dis J, 11, 408409.
65. Jacobs MR, 1995, Activity of quinolones against mycobacteria, Drugs, 49, suppl 2, 6775.
66. Jacobs WR Jr,, Barlett RG,, Udani R, et al, 1993, Rapid assessment of drug susceptibility of M. tuberculosis by means of luciferase reporter phages, Science, 260, 819822.
67. Jenkins JR,, Al-Kawi MZ,, Bashir R, 1987, Dynamic computed tomography of cerebral parenchymal tuberculomata, Neuroradiology, 29, 523529.
68. Ji B,, Lounis N,, Maslo C,, Truffot-Pernod C,, Bonnafous P,, Grosset J, 1998, In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 42, 20662069.
69. Ji B,, Lounis N,, Truffot-Pernot C,, Grosset J, 1995, In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 39, 13411344.
70. Ji B,, Truffot-Pernot C,, Grosset J, 1991, In vitro and in vivo activity of sparfloxacin (AT 4140) against Mycobacterium tuberculosis, Tubercle, 72, 181186.
71. Jindani A,, Aber VR,, Edwards EA,, Mitchinson DA, 1980, The early bactericidal activity of drugs in patients with pulmonary tuberculosis, Am Rev Resp Dis, 121, 939949.
72. Kahana LM,, Spino M, 1991, Ciprofloxacin in patients with mycobacterial infections, experience in 15 patients, DICP Ann Pharmacother, 25, 919924.
73. Kamat SR, 1998, Early experience with sparfloxacin in tuberculosis, J Assoc Physicians India, 46, 827828.
74. Kapila K,, Chysky V,, Accieri G,, Schacht P,, Echols R, 1990, Worldwide clinical experience on safety of ciprofloxacin in children on compassionate use basis, Third Intern Symp New Quinolones, Vancouver.
75. Kapur V,, Li LL,, Hamrick MR,, Plikaytis BB,, Shinnick TM,, Telenti A,, Jacobs WR Jr,, Banerjee A,, Cole S,, Yuen KY,, Clarridge JE III,, Kreiswirth BN,, Mussen JM, 1995, Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis by automated DNA sequencing, Arch Pathol Lab Med, 119, 131138.
76. Karak K,, De PK, 1995, Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis, Indian J Med Res, 101, 147149.
77. Kasai H,, Ezaki T,, Harayama S, 2000, Differentiation of phylogenetically related slowly growing mycobacteria by their gyrB sequences, J Clin Microbiol, 38, 301308.
78. Kennedy N,, Berger L,, Curram L, et al, 1996, Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of tuberculosis, Clin Infect Dis, 22, 827833.
79. Kennedy NR,, Fox GM,, Kisyombe GM,, Saruni AOS,, Uiso LO,, Ramsay ARC,, Ngowi FI,, Gillespie SH, 1993a, Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis, Am Rev Resp Dis, 148, 15471551.
80. Kennedy NR,, Fox R,, Uiso L,, Ngowi FI,, Gillespie SH, 1993b, Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis, J Antimicrob Chemother, 32, 897902.
81. Klemens SP,, Sharpe CA,, Rogge MC,, Cynamon M, 1994, In vitro activity of ofloxacin against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 38, 14761479.
82. Kocagöz T,, Hackbarth CJ,, Ünsal I,, Rosenberg EY,, Nikaido H,, Chambers HF, 1996, Gyrase mutations in laboratory-selected fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra, Antimicrob Agents Chemother, 40, 17681774.
83. Kohno SH,, Koga H,, Kaku M,, Maesaki S,, Hara K, 1992, Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis, Chest, 102, 18151818.
84. Kolek B,, Huczko E,, Aleksunes L,, Minassian B,, Valera L,, Stickle T,, Bonner D,, Fung-Tomc J, 2000, The in vitro activity of the novel des-fluoro (6) quinolone BMS-284,756 against anaerobes, Mycoplasma, Ureaplasma, Chlamydia and Mycobacterium spp., 40th Intersci Conf Antimicrob Agents Chemother.
85. La Bombardi VJ,, Cataldo-Caputzal L, 1993, Ciprofloxacin susceptibility testing by MIC and disk elution of drug-resistant Mycobacterium tuberculosis and Mycobacterium avium complex, Antimicrob Agents Chemother, 37, 15561557.
86. Lalande V,, Truffot-Pernot C,, Paccaly-Moulin A,, Grosset J,, Ji B, 1993, Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice, Antimicrob Agents Chemother, 37, 407411.
87. Leysen DC,, Haemers A,, Pattyn SR, 1989, Mycobacteria and the new quinolones, Antimicrob Agents Chemother, 33, 15.
88. Linseman DA,, Hampton LA,, Branstetter DG, 1995, Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin, Appl Toxicol, 28, 5964.
89. Liu J,, Takiff HE,, Nikaido H, 1996, Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump, J Bacteriol, 178, 37913795.
90. Loebstein R,, Addis A,, Ho E, et al, 1998, Pregnancy outcome following gestational exposure to fluoroquinolones, a multicenter, prospective, controlled study, Antimicrob Agents Chemother, 42, 13361339.
91. Lounis N,, Ji B,, Truffot-Pernot C,, Grosset J, 1997, Which amino-glycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother, 41, 607610.
92. Lubasch A,, Erbes R,, Mauch H,, Lode H, 2001, Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy, Eur Resp J, 17, 641646.
93. Madhusudan K,, Ramesh V,, Nagaraja V, 1994, Molecular cloning of gyr A and gyr B genes of Mycobacterium tuberculosis, analysis of nucleotide sequence, Biochem Mol Biol Intern, 33, 651660.
94. Mangunnegoro H,, Hudoyo A, 1999, Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia, Chemotherapy, 45, Suppl 2, 1935.
95. Mariandyshev AO,, Klinberg NM,, Shobina AI,, Moroz MI, 1997, Use of Maxaquin® in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens, Probl Tuberk, 4, 1921.
96. McDonough KA,, Kress Y, 1995, Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis, Infect Immun, 63, 48024811.
97. Mitchison DA, 1995, Early bactericidal activity and sterilizing activity of ciprofloxacin in pulmonary tuberculosis, Am J Resp Crit Care Med, 151, 921922.
98. Mitchison DA,, Nunn AJ, 1986, Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis, Am Rev Resp Dis, 133, 423429.
99. Miyazaki E,, Miyazaki M,, Chen JM,, Chaisson RE,, Bishai WR, 1999, Moxifloxacin (BAY 12-8039), a new 8-methoxy quinolone, is active in a mouse model of tuberculosis, Antimicrob Agents Chemother, 43, 8589.
100. Mohanty KC,, Dhamgaye TM, 1993, Controlled trial of ciprofloxacin short-term chemotherapy for pulmonary tuberculosis, Chest, 104, 11941198.
101. Mor N,, Vanderkork J,, Heiflets L, 1994, Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages, Antimicrob Agents Chemother, 38, 11611164.
102. Mozhokina GN,, Kunichan AD,, Levchenko TN,, Smirnova NS, 1998, Mechanism of action of lomefloxacin on Mycobacterium tuberculosis, Antibiot Khimiother, 43, 1316.
103. Nakae I,, Nakatoni K,, Inoue S, et al, 1991, Therapeutic effects of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patients, Chest Disease Cooperative Study Unit of National Sanatorium in Kinki District, Kekkaku, 66, 299307.
104. Niemann S,, Harmsen D,, Ruesch-Gerdes S,, Richter E, 2000, Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyr B DNA sequence polymorphism analysis, J Clin Microbiol, 38, 32313234.
105. O’Brien RJ, 1993, Ciprofloxacin is not a component of first-line TB, Chest, 104, 1312.
106. Ogasawara K,, Sato K,, Tamioka H, 2000, Comparative in vitro antimicrobial activity of the newly synthesized quinolones WQ-3034 and HSR-903 and other quinolones against Mycobacterium tuberculosis and Mycobacterium avium complex, Jpn J Chemother, 48, 892897.
107. Onodera Y,, Tanaka M,, Sato K, 2001, Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis, J Antimicrob Chemother, 47, 447450.
108. Pandeya SN,, Sriram D,, Yogeeswari P,, Ananthan S, 2001, Antituberculous activity of norfloxacin Mannich bases with isatin derivatives, Chemotherapy, 47, 266269.
109. Pattyn SR,, Van, Caekenberghe DL,, Verhoeven JR, 1987, In vitro activity of five quinolones against cultivable mycobacteria, Eur J Clin Microbiol, 6, 572573.
110. Peloquin CA,, Beaning SE,, Huitt GW,, Heman MD, 1998, Levofloxacin for drug resistant Mycobacterium tuberculosis, Ann Pharmacother, 32, 268269.
111. Piersimoni G,, Morbiducci V,, Bornigia S,, De Sio G,, Scalise G, 1992, In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis, Am Rev Respir Dis, 146, 14451447.
112. Rao S, 1995, An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis, Tubercle Lung Dis, 76, 219222.
113. Rastogi N,, Blom-Potar MC, 1990, Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Ra multiplying in the J-774 macrophage cell line, Zentralbl Bakteriol, 273, 195199.
114. Rastogi N,, Goh KS, 1991, In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin, Antimicrob Agents Chemother, 35, 19331936.
115. Rastogi N,, Goh KS,, Bryskier A,, Devallois A, 1996, In vitro activities of levofloxacin used alone and in combination with first and second line antituberculous drugs against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 40, 16101616.
116. Rastogi N,, Potar MC,, David HL, 1987, Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774, ultrastructure and drug susceptibility studies, Current Microbiol, 16, 7992.
117. Rastogi N,, Ross BC,, Dwyer B,, Goh KS,, Clavel-Sérès S,, Jeantils V,, Gruaud P, 1992, Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis, Eur J Clin Microbiol Infect Dis, 11, 901907.
118. Renau TE,, Gage JW,, Dever JA,, Roland GE,, Joannides ET,, Shapiro MA,, Sanchez JP,, Grachek SJ,, Domagala JM,, Jacobs MR,, Reynolds RC, 1996a, Structure-activity relationships of quinolone agents against mycobacteria, effect of structural modifications at the 8 position, Antimicrob Agents Chemother, 40, 23632368.
119. Renau TE,, Sanchez JP,, Gage JW,, Dever JA,, Shapiro MA,, Grachek SJ,, Domagala JM, 1996b, Structure-activity relationships of the quinolone antibacterials against mycobacteria, effect of structural changes at N-1 and C-7, J Med Chem, 39, 729735.
120. Renau TE,, Sanchez JP,, Shapiro MA,, Dever JA,, Grachek SJ,, Domagala JM, 1995, Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria, J Med Chem, 38, 29742977.
121. Ridzon R,, Meador J,, Maxwell R, et al, 1997, Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin, Clin Infect Dis, 24, 12641265.
122. Rodriguez JC,, Ruiz M,, Climent A,, Royo G, 2001, In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis, Inter J Antimicrob Agents, 17, 229231.
123. Ruiz-Serrano MJ,, Alcala L,, Martinez L,, Diaz M,, Marin M,, Gonzalez-Abad MJ,, Bouza E, 2000, In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs, Antimicrob Agents Chemother, 44, 25672568.
124. Sahoo RC, 1993, Ofloxacin in the retreatment of patients with pulmonary tuberculosis resistance to isoniazid, streptomycin and rifampicin, a South Indian experience, Tubercle Lung Dis, 74, 140141.
125. Saito H,, Sato K,, Tomioka H,, Dekio S, 1994, In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a, Antimicrob Agents Chemother, 38, 28772882.
126. Saito H,, Tomioka H,, Sato K, 1994, In vitro antimycobacterial activity of the new quinolone OPC-17116, Chemotherapy, 42, 15.
127. Salfinger M,, Hohl P,, Kafader FM, 1988, Comparative in vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria, J Antimicrob Chemother, 22, suppl D, 5563.
128. Sander P,, Alcaide F,, Richter I,, Frischkosn K,, Tortoli E,, Springer B,, Telenti A,, Boettger EC, 1998, Inteins in mycobacterial gyr A are a taxonomic character, Microbiology, 144, 589591.
129. Sato K,, Tomioka H, 1999, Antimicrobial activities of benzoxazino rifampicin (KRM-1648) and clarithromycin against Mycobacterium avium intracellulare complex residing in murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells, J Antimicrob Chemother, 43, 351357.
130. Sato K,, Tomioka H,, Akaki T,, Kawahara S, 2000, Antimicrobial activities of levofloxacin, clarithromycin and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within mono Mac 6 human macrophage and A-549 type II alveolar cell line, Inter J Antimicrob Agents, 16, 2529.
131. Schaberg T,, Specht S,, Stephan H,, Lode H, 1995, Use of sparfloxacin for the treatment of multidrug resistant pulmonary tuberculosis, Tubercle Lung Dis, 76, suppl 2, 091-PA 11, 86.
132. Shah A,, Bhagat R,, Panchal N, 1993, Resistant tuberculosis, successful treatment with amikacin, ofloxacin, clofazimine and PAS, Tubercle Lung Dis, 74, 6467.
133. Sindelar G,, Zhao X,, Liew A,, Dong Y,, Lu T,, Zhou J,, Domagala J,, Drlica K, 2000, Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria, Antimicrob Agents Chemother, 44, 33373343.
134. Sirgel FA,, Botha FJ,, Parkin DP,, Van den Wal BW,, Schall R,, Donald PR,, Mitchison DA, 1997, The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis, Am J Respir Crit Care Med, 156, 901905.
135. Sirgel FA,, Venter A,, Heilmann HD, 1995, Comparative in vitro activity of BAY y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex, J Antimicrob Chemother, 35, 349351.
136. Sokolova GB,, Kunichan AD,, Koriakin YA,, Lazareva IV, 1998, Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis, Antibiot Khimiother, 43, 1012.
137. Sokolova GB,, Mozhokina GN,, Kunichan AD,, Elistratova NA,, Perelman ML, 2000, Maxaquin® in the combined treatment of tuberculosis, Probl Tuberk, 5, 3539.
138. Stevens JP,, Daniel TM, 1995, Chemoprophylaxis of multidrug-resistant tuberculosis infections in HIV-uninfected individual using ciprofloxacin and pyrazinamide, a decision analysis, Chest, 108, 712717.
139. Sullivan EA,, Kreiswirth BN,, Palumbo L,, Kapur V,, Musser JH,, Ebrahimazedeh A,, Frieden TR, 1995, Emergence of fluoroquinolone resistant tuberculosis in New York City, Lancet, 345, 11481150.
140. Takahata M,, Mitsuyama J,, Yamashino Y,, Yonezawa M,, Araki H,, Todo Y,, Minami S,, Watanabe Y,, Naritu H, 1999, In vitro and in vivo activities of T-3811 ME, a novel des-F(6) quinolone, Antimicrob Agents Chemother, 43, 10771084.
141. Takemura M,, Takahashi H,, Kawakami K,, Namba K,, Tanaka M,, Miyanchi R, 2001, Novel anti-acid-fast bacterial agents containing pyridonecarboxylic acids, WO-00158876-2001.
142. Takiff HE,, Cimino M,, Musso MC,, Weisbrod T,, Martinez R,, Delgado MB,, Salazar L,, Bloom BR,, Jabcos WR Jr, 1996, Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis, Proc Natl Acad Sci USA, 93, 362366.
143. Takiff HE,, Salazar H,, Guerrero C,, Philipp W,, Huang WM,, Kreiswirth B,, Cole ST,, Jacobs WR,, Telenti A, 1994, Cloning and nucleotide sequence of M. tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations, Antimicrob Agents Chemother, 38, 773780.
144. Texier-Maugein J,, Mormede M,, Fourche J,, Bébéar C, 1987, In vitro activity of fluoroquinolones against eighty-six isolates of mycobacteria, Eur J Clin Microbiol, 6, 584586.
145. Tomioka H,, Saito H,, Sato K, 1993a, Comparative antimycobacterial activity of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin, Antimicrob Agents Chemother, 37, 12591263.
146. Tomioka H,, Sato K,, Akaki T,, Kajitani H,, Kawahara S,, Sakatani M, 1999, Comparative in vitro antimicrobial activities of the newly synthesized quinolones HSR-903, sitafloxacin (DU 6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex, Antimicrob Agents Chemother, 43, 30013004.
147. Tomioka H,, Sato K,, Kajitani H,, Akaki T,, Shishido S, 2000, Comparative antibacterial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex, Antimicrob Agents Chemother, 44, 283286.
148. Tomioka H,, Sato K,, Saito H, 1991, Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria, Tubercle, 72, 181186.
149. Tomioka H,, Sato K,, Saito H, 1993b, In vitro antimycobacterial activity of a new quinolone, NM 934, Kekkaku, 68, 517520.
150. Tomioka H,, Sato K,, Saito K,, Ikeda Y, 1992, Antimycobacterial activity of a newly synthesized fluoroquinolone, Y 26,611, Kekkaku, 67, 515520.
151. Trimble KA,, Clark RB,, Sanders WE Jr,, Frankel JW,, Cacciatore R,, Valdez H, 1987, Activity of ciprofloxacin against Mycobacterium in vitro, comparison of BACTEC and macrobroth dilution methods, J Antimicrob Chemother, 19, 617622.
152. Truffot-Pernot C,, Ji B,, Grosset J, 1991, Activities of pefloxacin and ofloxacin against mycobacteria, in vitro and mouse experiments, Tubercle, 72, 5764.
153. Tsukamura M, 1985a, Antituberculosis activity of ofloxacin (DL-8280) on experimental tuberculosis in mice, Am Rev Respir Dis, 132, 915.
154. Tsukamura M, 1985b, In vitro antituberculosis activity of a new antibacterial substance, ofloxacin (DL 8280), Am Rev Respir Dis, 131, 348351.
155. Tsukamura M, 1986, Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin), Microbiol Immunol, 30, 931933.
156. Tsukamura M,, Mizuno S, 1986, Differentiation between mycobacterial species by the susceptibility test to ciprofloxacin: comparison of antimycobacterial spectrum between ofloxacin and ciprofloxacin, Kekkaku, 61, 357359.
157. Tsukamura M,, Nakamura E,, Yoshii S,, Yanase M,, Yasuda Y,, Amano H, 1985, Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis, Am Rev Respir Dis, 131, 352356.
158. Uttley AHC,, Collins CH, 1988, In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against Mycobacterium tuberculosis, Tubercle, 69, 193195.
159. Vacher S,, Pellegrin JL,, Leblanc F,, Fourche J,, Mangeiro J, 1999, Comparative antimycobacterial activity of ofloxacin, ciprofloxacin and grepafloxacin, J Antimicrob Chemother, 44, 647652.
160. Van Caekenberghe D, 1990, Comparative in vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp., J Antimicrob Chemother, 26, 381386.
161. Van Rensburg CEJ,, Joone GK,, Anderson R, 1995, An in vitro investigation of the bioactivities of a ciprofloxacin and the new fluoroquinolone agent clinafloxacin (CI-960) and PD 131,628 against Mycobacterium tuberculosis in human macrophages, Chemotherapy, 41, 234238.
162. Wanger A,, Mills K, 1994, Etest for susceptibility testing of Mycobacterium tuberculosis and Mycobacterium avium-intracellulare, Diagn Microbiol Infect Dis, 19, 179181.
163. Wesenfelder L,, Eugene C, 1993, Tuberculose péritonéale décapitée par les fluoroquinolones chez un malade atteint de cirrhose, Gastroenterol Clin Biol, 17, 765.
164. Willcox PA,, Groenwald PJ,, Mackenzie CR, 1993, Ofloxacin-based chemotherapy in multiply drug-resistant pulmonary tuberculosis, Drugs, 45, Suppl 3, 223224.
165. Wise R,, Ashby JP,, Andews JM, 1988, In vitro activity of PD 127,391, an enhanced-spectrum quinolone, Antimicrob Agents Chemother, 32, 12511256.
166. Woodcock JH,, Andrews JM,, Boswell FJ,, Brenwald NP,, Wise R, 1997, In vitro activity of BAY 12-8039, a new fluoroquinolone, Antimicrob Agents Chemother, 41, 101106.
167. Xu C,, Kreiswith BN,, Sreevatsan S,, Musser JM,, Drlica K, 1996, Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multi-drug resistant Mycobacterium tuberculosis, J Infect Dis, 174, 11271130.
168. Yamane N,, Chilima BZ,, Okuzawa Y,, Tanno K, 1996, Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis, comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media, Kekkaku, 71, 453458.
169. Yew WW,, Chan CH,, Wong PC,, Lee J,, Wong CF,, Cheung SW,, Chan SY,, Cheng AFB, 1995, Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction, Drugs Exptl Clin Res, 21, 7983.
170. Yew WW,, Chan CK,, Chan CH,, Tam CM,, Leung CC,, Wong PC,, Lee J, 2000, Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens, Chest, 117, 744751.
171. Yew WW,, Kwan SY,, Ma WK,, Khin MA,, Chan PY, 1990, In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis, J Antimicrob Chemother, 26, 227236.
172. Yew WW,, Lee J,, Wong PC,, Kwan SYL, 1992, Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction, Int J Clin Pharmacol Res, 12, 173178.
173. Yew WW,, Piddock LVJ,, Li MSK,, Lyon D,, Chan CY,, Cheng AFB, 1994, In vitro activity of quinolones and macrolides against mycobacteria, J Antimicrob Chemother, 34, 343351.
174. Yew WW,, Wong CF,, Wong PC, et al, 1993, Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after co-administration of cycloserine and ofloxacin, Clin Infect Dis, 17, 288289.
175. Young L,, Berlin OGW,, Inderlied CB, 1987, Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria, Am J Med, 82, suppl 4A, 2326.
176. Zhao BY,, Pine R,, Domagala J,, Drlica K, 1999, Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis, effects of a C-8 methoxy group on survival in liquid media in human macrophages, Antimicrob Agents Chemother, 43, 661666.

Tables

Generic image for table
Table 1

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 2

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 3

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 4

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 5

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 6

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 7

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 8

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 9

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 10

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 11

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 12

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 13

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 14

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 15

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 16

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 17

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 18

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 19

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 20

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 21

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 22

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44
Generic image for table
Table 23

Citation: Bryskier A, Lowther J. 2005. Fluoroquinolones and Tuberculosis: a Review, p 1124-1145. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch44

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error